Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06274528 · ClinicalTrials.gov registry record · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
A Phase 2 study of Alzheimer Disease, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 201
- Enrollment target
- 1
- Study location
NCT06274528 is a Phase 2 study of Alzheimer Disease that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 201 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06274528, a Phase 2 study of Alzheimer Disease, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 201 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lemborexant 10 mg
- DRUG Lemborexant 20mg
Study Locations (1)
Missouri
- Washington University in St. Louis, School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2024-03-11 |
| Est. Completion | 2029-03-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06274528
The ClinicalTrials.gov registry entry for NCT06274528 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (93% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06274528 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT06274528 about?
NCT06274528 is a clinical study titled "DORA and LP in Alzheimer's Disease Biomarkers". The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.
What is the current status of trial NCT06274528?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 201 participants. The study started on 2024-03-11. Estimated completion is 2029-03-11.
What conditions does trial NCT06274528 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT06274528?
The interventions under investigation include: Placebo (DRUG), Lemborexant 10 mg (DRUG), Lemborexant 20mg (DRUG).
Who is sponsoring clinical trial NCT06274528?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06274528 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.